Medication Treatment Study for snOH in Subjects with Primary Autonomic Failure

Clinical Trial Title

Phase 3 clinical effect of TD-9855 for treating snOH in subjects with primary autonomic failure.

Contact Information

Clinical Trial Protocol Description:

The SEQUOIA Study is a research study looking at a study drug for people with conditions such as Parkinson’s disease (PD) or multiple system atrophy (MSA) who have a drop in blood pressure upon standing. We want to learn how safe the study drug is and whether it can reduce these symptoms. Participation will last about 9 weeks, with 7 study visits.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have been diagnosed with Parkinson’s disease (PD) or multiple system atrophy (MSA),
  • Have symptoms such as dizziness, light-headedness, feeling faint, or feeling like you might black out upon standing.
  • Are 30 years of age or older.
  • Meet additional eligibility criteria.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Katie Kompoliti, MD

Contact Information

Samantha Ruehl

(312) 563-2900
Press 4
Code: Sequoia 0169


Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more